Medtronic Cash Flow Statement
NYSE: MDTHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Medtronic free cash flow
In fiscal 2026, Medtronic generated $7.33 billion of operating cash flow and spent $1.90 billion on capital expenditures. That left free cash flow of $5.43 billion, a free-cash-flow margin of 14.9% of revenue. Free cash flow was up 4.6% from the prior year's $5.18 billion.
Medtronic returned $4.67 billion to shareholders: $3.64 billion in dividends and $1.03 billion in share repurchases, equal to 86% of free cash flow. Free cash flow covered dividend payments 1.5 times.
Summary generated from market data by MetaCap's automated system. Methodology
Medtronic cash flow statement (annual)
| Fiscal year (USD) | FY 20262026-04-24 | FY 20252025-04-25 | FY 20242024-04-26 | FY 20232023-04-28 | FY 20222022-04-29 | FY 20212021-04-30 | FY 20202020-04-24 | FY 20192019-04-26 | FY 20182018-04-27 | FY 20172017-04-28 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 4.84B | 4.69B | 3.71B | 3.78B | 5.06B | 3.63B | 4.81B | 4.65B | 3.10B | 4.02B |
| Net Income growth (YoY) | +3.11% | +26.61% | -2.09% | -25.25% | +39.45% | -24.47% | +3.35% | +50.24% | -23.09% | +13.74% |
| Depreciation & Amortization | 2.96B | 2.86B | 2.65B | 2.70B | 2.71B | 2.70B | 2.66B | 2.66B | 2.64B | 2.92B |
| Stock-Based Compensation | 457.00M | 429.00M | 393.00M | 355.00M | 359.00M | 344.00M | 297.00M | 290.00M | 344.00M | 348.00M |
| Change in Working Capital | -358.00M | -83.00M | 252.00M | -243.00M | -347.00M | 609.00M | -621.00M | 125.00M | -127.00M | 129.00M |
| Operating Cash Flow | 7.33B | 7.04B | 6.79B | 6.04B | 7.35B | 6.24B | 7.23B | 7.01B | 4.68B | 6.88B |
| Capital Expenditures | -1.90B | -1.86B | -1.59B | -1.46B | -1.37B | -1.35B | -1.21B | -1.13B | -1.07B | -1.25B |
| Investing Cash Flow | -2.93B | -1.94B | -2.37B | -3.49B | -1.66B | -2.87B | -3.20B | -774.00M | 5.86B | -1.57B |
| Dividends Paid | -3.64B | -3.59B | -3.67B | -3.62B | -3.38B | -3.12B | -2.89B | -2.69B | -2.49B | -2.38B |
| Share Repurchases | -1.03B | -3.23B | -2.14B | -645.00M | -2.54B | -652.00M | -1.33B | -2.88B | -2.17B | -3.54B |
| Debt Issued | 1.75B | 3.21B | 0 | 5.41B | 0 | 7.17B | 5.57B | 7.79B | 21.00M | 2.14B |
| Debt Repaid | -2.93B | 0 | 0 | -6.01B | -1.00M | -7.37B | -6.11B | -7.95B | -7.37B | -863.00M |
| Financing Cash Flow | -4.75B | -4.36B | -4.45B | -4.96B | -5.34B | -4.14B | -4.20B | -5.43B | -11.95B | -3.28B |
| Net Change in Cash | -269.00M | 934.00M | -259.00M | -2.17B | 121.00M | -547.00M | -253.00M | 724.00M | -1.30B | 2.09B |
| Free Cash Flow | 5.43B | 5.18B | 5.20B | 4.58B | 5.98B | 4.88B | 6.02B | 5.87B | 3.62B | 5.63B |
This table shows 10 annual periods of Medtronic's cash flow statement, from FY 2026 back to FY 2017, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow MDT's reporting calendar. What is a cash flow statement?